Promius Pharma, LLC Launches Scytera(TM) (Coal Tar) Foam 2% for Treatment of Psoriasis
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Promius Pharma, LLC, has launched Scytera™ (coal tar) Foam 2% for the treatment of chronic psoriasis, a skin disease that affects approximately 7.5 million Americans according to The National Psoriasis Foundation. Scytera Foam delivers coal tar in a cosmetically-elegant, patient-pleasing foam vehicle.